FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL								
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Scanlar (Last) C/O TRE	nd Address of 1 Sean F. (F) EACE MED	_ TI TN 3.1	2. Issuer Name and Ticker or Trading Symbol TREACE MEDICAL CONCEPTS, INC. TMCI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Tother (specify below) 3. Date of Earliest Transaction (Month/Day/Year) 11/14/2022 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Tother (specify below) SVP, Marketing										vner						
100 PALMETTO PARK PLACE (Street) PONTE VEDRA FL 32081 (City) (State) (Zip)							4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - N	Non-Deri	vativ	e Sec	curit	ties A	cquire	ed, D	isposed o	f, or B	enefic	ally	Owned				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/You						Execution Date,		3. Transaction Code (Instr. 8) 4. Securities A Disposed Of (5)	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
						Code V Amount (A) or Price		Price		Transaction(s) (Instr. 3 and 4)				(Instr. 4)					
Common Stock 11/14/202					2022				M ⁽¹⁾		25,000	Α	\$0.	1	34,975(2)			D	
Common Stock 11/14/202									S ⁽¹⁾		25,000	D	\$24.26	9,975				D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		D	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Í	Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amou or Numb of Share	er					
Stock Option (Right to Buy)	\$0.1	11/14/2022			M ⁽¹⁾			25,000	12/15	5/2018	12/15/2024	Common Stock	ⁿ 25,0	00	\$0.1	108,750	0	D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- 2. Includes 9 975 RSUs

Remarks:

/s/ Lisa Taylor as Attorney-infact for Sean Scanlan

11/16/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{3.} The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from \$23.8000 to \$24.5500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.